Adenosine A2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats

被引:98
作者
Koga, K [1 ]
Kurokawa, M [1 ]
Ochi, M [1 ]
Nakamura, J [1 ]
Kuwana, Y [1 ]
机构
[1] Kyowa Hakko Kogyo Co Ltd, Pharmaceut Res Inst, Nagaizumi, Shizuoka 4118731, Japan
关键词
KF17837 ((E)-1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methyl-3,7-dihydro-1H-purine-2,6-dione); KW-6002 ((E)-1,3-diethyl-8-(3,4-dimethoxystyryl)-7-methyl-3,7-dihydro-1H-purine-2,6-dione); Parkinson's disease; adenosine A(2) receptor antagonist; 6-hydroxydopamine;
D O I
10.1016/S0014-2999(00)00745-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of novel adenosine A(2A) receptor antagonists KF17837 ((E)-1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methyl-3,7-dihydro-1H-purine-2,6-dione) and KW-6002 ((E)-1,3-diethyl-8-(3,4-dimethoxystyryl) -7-methyl-3,7-dihydro-1H-purine-2,6-dione), on rotational behavior induced by apomorphine or L-DOPA (L-3,4-dihydroxyphenylalanine) were investigated in rats with unilateral 6-hydroxydopamine lesions. Both KF17837 and KW-6002 slightly induced rotational behavior per se. However, KF17837 and KW-6002 significantly increased the total counts of turning induced by apomorphine at doses of 3 mg/kg, p.o. and 10 mg/kg, p.o., and at doses of 1 mg/kg, p.o. and higher, respectively. KF17837 and KW-6002 also potentiated the rotational behavior induced by L-DOPA at a dose of 3 mg/kg, p.o. Furthermore, i.c.v. injection (10 mug/20 yl) of a. selective adenosine A(2) receptor agonist CGS 21680 {2[p-(2-carboxy-ethyl)phenethylamino]-5'-N-ethylcarboxamidoadenosine} partially prevented the rotational behavior induced by apomorphine and this inhibition was reversed by KW-6002 (1 mg/kg, p.o.). The increase in total counts of apomorphine-induced turning by the adenosine A,, receptor antagonists seems to be mainly attributable to prolongation of turning duration rather than enhancement of intensity. These results suggest that these adenosine A, receptor antagonists may be useful to ameliorate shortening in the duration of dopaminergic drug response in patients with advanced Parkinson's disease. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:249 / 255
页数:7
相关论文
共 26 条
[1]   Tissue distribution of adenosine receptor mRNAs in the rat [J].
Dixon, AK ;
Gubitz, AK ;
Sirinathsinghji, DJS ;
Richardson, PJ ;
Freeman, TC .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (06) :1461-1468
[2]   Adenosine A(2A) receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats [J].
Fenu, S ;
Pinna, A ;
Ongini, E ;
Morelli, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 321 (02) :143-147
[3]  
FREDHOLM BB, 1994, PHARMACOL REV, V46, P143
[4]  
FUXE K, 1974, MED BIOL, V52, P48
[5]  
GARRETT BE, 1995, J PHARMACOL EXP THER, V274, P207
[6]   PHARMACOLOGICAL EFFECTS PRODUCED BY INTRACEREBRAL INJECTION OF DRUGS IN THE CONSCIOUS MOUSE [J].
HALEY, TJ ;
MCCORMICK, WG .
BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1957, 12 (01) :12-15
[7]   ADENOSINE RECEPTOR ANTAGONISTS POTENTIATE DOPAMINE RECEPTOR AGONIST-INDUCED ROTATIONAL BEHAVIOR IN 6-HYDROXYDOPAMINE-LESIONED RATS [J].
JIANG, H ;
JACKSONLEWIS, V ;
MUTHANE, U ;
DOLLISON, A ;
FERREIRA, M ;
ESPINOSA, A ;
PARSONS, B ;
PRZEDBORSKI, S .
BRAIN RESEARCH, 1993, 613 (02) :347-351
[8]   Combined use of the adenosine A2A antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys [J].
Kanda, T ;
Jackson, MJ ;
Smith, LA ;
Pearce, RKB ;
Nakamura, J ;
Kase, H ;
Kuwana, Y ;
Jenner, P .
EXPERIMENTAL NEUROLOGY, 2000, 162 (02) :321-327
[9]   Adenosine A2A receptors modify motor function in MPTP-treated common marmosets [J].
Kanda, T ;
Tashiro, T ;
Kuwana, Y ;
Jenner, P .
NEUROREPORT, 1998, 9 (12) :2857-2860
[10]   Adenosine A2A antagonist:: A novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys [J].
Kanda, T ;
Jackson, MJ ;
Smith, LA ;
Pearce, RKB ;
Nakamura, J ;
Kase, H ;
Kuwana, Y ;
Jenner, P .
ANNALS OF NEUROLOGY, 1998, 43 (04) :507-513